PETRUCCI, MARIA TERESA
 Distribuzione geografica
Continente #
NA - Nord America 1.832
EU - Europa 890
AS - Asia 199
AF - Africa 23
OC - Oceania 5
SA - Sud America 4
Totale 2.953
Nazione #
US - Stati Uniti d'America 1.820
IT - Italia 461
DE - Germania 146
IN - India 81
SE - Svezia 74
CN - Cina 54
SG - Singapore 37
RU - Federazione Russa 31
NL - Olanda 27
FI - Finlandia 26
FR - Francia 25
BG - Bulgaria 24
GB - Regno Unito 20
TG - Togo 19
TR - Turchia 12
CA - Canada 11
AT - Austria 9
IE - Irlanda 9
ES - Italia 8
RO - Romania 8
CH - Svizzera 7
UA - Ucraina 7
BE - Belgio 6
HK - Hong Kong 4
AU - Australia 3
ID - Indonesia 3
MY - Malesia 3
AR - Argentina 2
BR - Brasile 2
IR - Iran 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
JP - Giappone 1
PA - Panama 1
PL - Polonia 1
TH - Thailandia 1
Totale 2.953
Città #
Fairfield 298
Rome 233
Ashburn 202
Chandler 134
Woodbridge 131
Seattle 126
Houston 120
Wilmington 97
Cambridge 96
Ann Arbor 61
Princeton 47
Dearborn 42
Beijing 27
Plano 26
San Paolo di Civitate 24
Sofia 23
Paris 22
Boston 20
Fremont 20
Millbury 20
San Diego 20
Lomé 19
Lawrence 18
Des Moines 17
Fasano 17
New York 16
Andover 15
Tivoli 13
Falls Church 12
Helsinki 9
Dublin 8
Pune 8
Singapore 8
Toronto 8
Vienna 8
Los Angeles 7
Milan 7
Phoenix 7
Redwood City 7
Bremen 6
Brussels 6
Norwalk 6
Hefei 5
Istanbul 5
Washington 5
Amsterdam 4
Ancona 4
Artena 4
Madrid 4
Napoli 4
San Jose 4
Atlanta 3
Auburn Hills 3
Bern 3
Castel Gandolfo 3
Den Helder 3
Frosinone 3
Grafing 3
Jakarta 3
London 3
Zurich 3
Albuquerque 2
Ariccia 2
Barcelona 2
Bethesda 2
Boardman 2
Brescia 2
Camerino 2
Canary Wharf 2
Chicago 2
Codroipo 2
Ercolano 2
Federal 2
Fiuggi 2
Florence 2
Frankfurt am Main 2
Hangzhou 2
Hebei 2
Hong Kong 2
Leverano 2
Monterotondo 2
Naples 2
Nettuno 2
Oakville 2
Sacramento 2
San Mateo 2
Shanghai 2
Sydney 2
Acquaviva delle Fonti 1
Albano Laziale 1
Arnsberg 1
Auckland 1
Baltimore 1
Bari 1
Basildon 1
Berlin 1
Bologna 1
Bühl 1
Cassino 1
Chengdu 1
Totale 2.146
Nome #
Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: role of HSP70/TLR2/NF-kB axis 155
p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells 151
Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells. role of cMYC-IRF4-miR-125b interplay 150
The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma 136
Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle-associated MICA. Dual role in cancer immunosurveillance 123
Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms 118
Drug-induced senescent Multiple Myeloma cells elicit NK cell proliferation by direct or exosome-mediated IL-15 trans-presentation 111
The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in multiple myeloma. modulation by bromodomain and Extra-Terminal (BET) protein inhibitors 110
Biventricular assessment of light-chain amyloidosis using 3D speckle tracking echocardiography: differentiation from other forms of myocardial hypertrophy 106
Efficacy and safety of long term tenofovir in high risk patients with hematological malignancies (HM) to prevent Hepatitis B Virus (HBV) reactivation after immunosuppressive therapies in real life 95
Peripheral nociceptor sensitization mediates allodynia in patients with distal symmetric polyneuropathy 94
Bone marrow stromal cell-derived IL-8 upregulates PVR expression on multiple myeloma cells via NF-kB transcription factor 89
High expression levels of IP10/CXCL10 are associated with modulation of the natural killer cell compartment in multiple myeloma 88
Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment. 88
Key role of the CD56lowCD16low Natural Killer cell subset in the recognition and killing of Multiple Myeloma cells 83
MICA-129 dimorphism and soluble MICA are associated with the progression of multiple myeloma 81
Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells 80
Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies. 78
null 69
Phytochemical analysis and In vitro antileukemic activity of alkaloid-enriched extracts from Vinca sardoa (Stearn) Pignatti 66
Peripheral nociceptor sensitization mediates allodynia in patients with distal symmetric polyneuropathy 65
null 62
Inhibition of Glycogen Synthase Kinase-3 Increases NKG2D Ligand MICA Expression and Sensitivity to NK Cell-Mediated Cytotoxicity in Multiple Myeloma Cells: Role of STAT3 60
null 57
null 57
null 55
Acquired FXIII deficiency and AL amyloidosis: A case of a rare association 52
null 50
null 48
Che-1-induced inhibition of mTOR pathway enables stress-induced autophagy. 46
null 44
Doxorubicin–Mediated miR–433 Expression on Exosomes Promotes Bystander Senescence in Multiple Myeloma Cells in a DDR–Independent Manner 37
Venous thromboembolism prophylaxis in patients with multiple myeloma: where are we and where are we going? 35
Relapsed/Refractory Multiple Myeloma Patients. A Multicenter Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy 35
Clinical utility and physician perceptions of a digital platform for electronic patient-reported outcomes monitoring in patients with hematologic malignancies in real-world practice. 32
When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer 32
The Modern Age of Monoclonal Antibodies: The Revolution of Daratumumab 28
Cross-Dressing of Multiple Myeloma Cells Mediated by Extracellular Vesicles Conveying MIC and ULBP Ligands Promotes NK Cell Killing 24
GAS6/TAM signaling pathway controls MICA expression in multiple myeloma cells 22
null 22
Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment 20
Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells 20
Single Molecule Real-Time Sequencing of the M Protein (SMaRT M-Seq): Toward Personalized Medicine Approaches in Monoclonal Gammopathies 17
Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition 16
null 16
Che-1/AATF-induced transcriptionally active chromatin promotes cell proliferation in multiple myeloma 16
Clinical features and prognostic factors in solitary plasmacytoma 14
Cyclophosphamide's Addition in Relapsed/Refractory Multiple Myeloma Patients With Biochemical Progression During Lenalidomide-Dexamethasone Treatment 13
4. High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate. 13
NEDD8-activating enzyme inhibition potentiates the anti-myeloma activity of natural killer cells 11
Bendamustine and dexamethasone are an effective salvage regimen for patients with advanced multiple myeloma in a Home Care Unit program 10
P861: SIALOFUCOSYLATED STRUCTURES ENABLE PLATELET BINDING TO MYELOMA CELLS CONFERRING PROTECTION FROM NK-MEDIATED CYTOTOXICITY 9
Multiparametric Flow Cytometry in Newly Diagnosed Multiple Myeloma Patients: An Italian Monocentric Experience 8
Managing treatment-related peripheral neuropathy in patients with multiple myeloma. 8
Race for the Cure: From the Oldest to the Newest Monoclonal Antibodies for Multiple Myeloma Treatment 6
Tapentadol PR for pain syndromes in real life patients with hematological malignancy. 6
Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study 5
Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight 4
Sialofucosylation Enables Platelet Binding to Myeloma Cells via P-Selectin and Suppresses NK Cell-Mediated Cytotoxicity 4
null 4
The unclear role of VEGF in POEMS syndrome: therapeutic implications of neoangiogenesis in a rare plasma cell disorder 1
Totale 3.155
Categoria #
all - tutte 7.328
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.328


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019239 0 0 0 0 0 0 0 0 0 0 125 114
2019/2020644 67 20 14 41 65 90 86 65 85 58 31 22
2020/2021348 16 34 5 6 6 23 25 23 20 139 32 19
2021/2022442 6 14 33 18 62 19 19 38 49 32 76 76
2022/2023601 119 121 30 47 60 78 13 36 40 2 32 23
2023/2024435 15 63 31 43 62 93 24 36 20 48 0 0
Totale 3.155